ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OBLN Obalon Therapeutics Inc

3.05
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Obalon Therapeutics Inc NASDAQ:OBLN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.05 2.81 2.87 0 01:00:00

Withdrawal of a Registration Statement Withdrawal Request (rw Wd)

03/02/2023 11:05am

Edgar (US Regulatory)


  

 

February 2, 2023

 

VIA EDGAR

 

Securities and Exchange Commission 

Division of Corporation Finance 

Office of Industrial Applications and Services 

100 F Street, NE 

Washington, DC 20549 

Attn: Abby Adams

 

Re:    

ReShape Lifesciences Inc. 

Registration Statement on Form S-1 

Filed January 12, 2023 

File No. 333-269207

     

Ladies and Gentlemen:

 

ReShape Lifesciences Inc. hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the two letters that were filed under the submission type Form RW on February 2, 2023 with respect to the above-referenced registration statement, with such withdrawal to be effective immediately. While the substance of those filings, which were to withdraw the Company’s request to accelerate the effectiveness of the above-referenced registration statement, was correct, the filings were incorrectly labeled as a Form RW and should have been submitted as correspondence to the Commission. To be clear, the Company is not requesting to withdraw the above registration statement, merely the two Form RWs that were incorrectly tagged.

 

If you have any questions regarding this letter, please contact Brett Hanson, Fox Rothschild LLP, at (612) 607-7330.

 

Very truly yours,

 

/s/ Paul F. Hickey

 

Paul F. Hickey

President and Chief Executive Officer

 

 

1 Year Obalon Therapeutics Chart

1 Year Obalon Therapeutics Chart

1 Month Obalon Therapeutics Chart

1 Month Obalon Therapeutics Chart

Your Recent History

Delayed Upgrade Clock